Quoin Pharmaceuticals Stock (NASDAQ:QNRX)

Forecast Ownership Financials Chart

Previous Close

$8.32

52W Range

$5.01 - $54.95

50D Avg

$7.39

200D Avg

$15.98

Market Cap

$4.99M

Avg Vol (3M)

$286.79K

Beta

1.78

Div Yield

-

QNRX Company Profile

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

US

Employees

3

IPO Date

Aug 01, 2016

Website

QNRX Performance

QNRX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	-	$-9.38M	$-8.85M
Net Income	$-8.96B	$-8.69M	$-9.28M
EBITDA	-	$-9.27M	$-8.74M
Basic EPS	$-1.91K	$-9.64	$-22.97
Diluted EPS	$-1.91K	$-9.64	$-22.97

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 23Mar 14, 24 | 8:30 AM

Q3 23Nov 09, 23 | 8:30 AM

Q2 23Aug 07, 23 | 8:30 AM

Peer Comparison

Ticker	Company
BDRX	Biodexa Pharmaceuticals Plc
ALLR	Allarity Therapeutics, Inc.
VRAX	Virax Biolabs Group Limited
REVB	Revelation Biosciences, Inc.
CDIO	Cardio Diagnostics Holdings, Inc.
UNCY	Unicycive Therapeutics, Inc.